Page last updated: 2024-11-08

tautomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tautomycin: an inhibitor of protein phosphatases 1 and 2A; isolated from Streptomyces spiroverticillatus; MF: C42-H70-O12; exists as a tautomeric mixture in solution [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133562784
MeSH IDM0150443
PubMed CID440646
CHEMBL ID505512
CHEBI ID9414
SCHEMBL ID83891

Synonyms (13)

Synonym
tautomycin
C05372
AC1L99OL ,
CHEMBL505512 ,
chebi:9414 ,
bdbm50366883
tautomycin from streptomyces spiroverticillatus
CTK8E8541 ,
SCHEMBL83891
[(1r,2r,3r,6s,7s,10r)-10-[(2s,3s,6r,8s,9r)-3,9-dimethyl-8-[(3s)-3-methyl-4-oxo-pentyl]-1,7-dioxaspiro[5.5]undecan-2-yl]-3,7-dihydroxy-1-isopropyl-2-methoxy-6-methyl-5-oxo-undecyl] (3r)-3-hydroxy-3-(4-methyl-2,5-dioxo-3-furyl)propanoate
dnc014580
J-002353
Q7688965

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Substitution of C-terminal sequences from the PP2A catalytic subunit produced a chimeric enzyme, CRHM2, that was inhibited by toxins with dose-response characteristics of PP1 and not PP2A."( Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors.
Barik, S; Connor, JH; Honkanen, RE; Kleeman, T; Shenolikar, S, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)0.00070.00053.49849.7600AID164505
Serine/threonine-protein phosphatase 2A activatorHomo sapiens (human)IC50 (µMol)9.40009.40009.40009.4000AID164525
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Gallus gallus (chicken)IC50 (µMol)0.00530.00010.41982.9000AID164675; AID200735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of phosphoprotein phosphatase activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
positive regulation of protein dephosphorylationSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
negative regulation of protein dephosphorylationSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
regulation of phosphoprotein phosphatase activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
mitotic spindle organizationSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
phosphoprotein phosphatase activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
signaling receptor bindingSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein bindingSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
ATP bindingSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein tyrosine phosphatase activator activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein phosphatase regulator activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein homodimerization activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
metal ion bindingSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein phosphatase 2A bindingSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
peptidyl-prolyl cis-trans isomerase activitySerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
nucleusSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
nucleoplasmSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
extracellular exosomeSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
protein phosphatase type 2A complexSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
calcium channel complexSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
ATPase complexSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase 2A activatorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID422123Inhibition of PP2A2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Characterization of the tautomycetin biosynthetic gene cluster from Streptomyces griseochromogenes provides new insight into dialkylmaleic anhydride biosynthesis.
AID164675Observed inhibition activity of the compounds against protein phosphatases 2A (PP2A)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID200745Exogenous inhibition concentration of Serine/threonine protein phosphatase 2C (PP2B)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200557Inhibition of protein phosphatase 1 (PP1) was determined by standard phosphorylase inhibition assay2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.
AID200735Exogenous inhibition concentration of Serine/threonine protein phosphatase 2A (PP2A)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID164525Inhibition of protein phosphatase 2A (PP2A) was determined by standard phosphorylase a inhibition assay2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.
AID164505Observed inhibition activity of the compounds against protein phosphatases 1 (PP1)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID164524Inhibition of protein phosphatase 2A (PP2A) was determined by standard phosphorylase inhibition assay2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.
AID226995Selectivity ratio for inhibition of Protein phosphatase 1 and Protein phosphatase 2A2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.
AID200749Exogenous inhibition concentration of Serine/threonine protein phosphatase 2C (PP2C); NI means no inhibition.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200556Inhibition of protein phosphatase 1 (PP1) was determined by standard phosphorylase a inhibition assay2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.
AID200561Exogenous inhibition of Serine/threonine protein phosphatase 1 (PP1)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID422122Inhibition of PP12009Journal of natural products, Mar-27, Volume: 72, Issue:3
Characterization of the tautomycetin biosynthetic gene cluster from Streptomyces griseochromogenes provides new insight into dialkylmaleic anhydride biosynthesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (111)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (2.70)18.7374
1990's56 (50.45)18.2507
2000's42 (37.84)29.6817
2010's10 (9.01)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.70 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews12 (10.62%)6.00%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other101 (89.38%)84.16%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]